Convalescent plasma therapy for COVID-19

Sangmeshwar Yewange; Deshpande Renuka; Vidyasagar Gali; Shyamlila B. Bavage; Nandkishor B. Bavage

Convalescent plasma therapy for COVID-19

Authors: Sangmeshwar Yewange, Deshpande Renuka, Vidyasagar Gali, Shyamlila B. Bavage, Nandkishor B. Bavage

Unique Paper ID: 149450
Volume: 6
Issue: 12
PageNo: 387-390

Keywords: SARS-CoV-2 COVID-19 Convalescent Plasma Therapy

Abstract:
The discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the outbreak of coronavirus disease 2019 (COVID-19) are causing public health emergency. A handful of literatures have summarized its clinical and radiologic features, whereas therapies for COVID-19 are rather limited. In order to evaluate the efficacy of convalescent plasma therapy in COVID-19 patients, we did this timely descriptive study. 6 laboratory confirmed COVID-19 patients were enrolled and received the transfusion of ABO-compatible convalescent plasma. The efficacy of this intervention was determined by the alleviation of symptoms, changes in radiologic abnormalities and laboratory tests. No obvious adverse effect observed during the treatment. Transfusion of convalescent plasma led to a resolution of ground glass opacities (GGOs) and consolidation in patient #1, #2, #3, #4 and #6. In patient #1 and #5 who presented with SARS-CoV-2 in throat swab, convalescent plasma therapy elicited an elimination of virus. Serologic analysis indicated an immediate increase in anti-SARS-CoV-2 antibody titers in patient #2 and #3, but not in patient #1. This study indicates that convalescent plasma therapy is effective and specific for COVID-19. This intervention has a special significance for eliminating SARS-CoV-2 and is believed to be a promising state-of-art therapy during COVID-19 pandemic crisis.

Download article

email to a friend

Cite This Article

ISSN: 2349-6002
Volume: 6
Issue: 12
PageNo: 387-390

Convalescent plasma therapy for COVID-19

Available:https://ijirt.org/Article?manuscript=149450

11 Jan, 2022

EVALUATION OF MARKETED EFFERVESCENT TABLETS

13 Oct, 2021

Bacterial Biofilm Inhibitor

02 Aug, 2021

The risk of death caused by the use of norepinephrine-resistant hypotension in the condition of septic shock in a patient

02 Aug, 2021

COMPUTER AIDED DRUG DESIGN (CADD)

29 Jul, 2021

Impact : Of Second Wave Covid-19 In world

29 Jul, 2021

The use of milrinone for curing a chronic heart failure

26 Jul, 2021

Leprosy Disease review

20 Jul, 2021

Transdermal Drug Delivery System

13 Jul, 2021

IBUPROFEN: AN OVERVIEW

13 Jul, 2021

CHEMOTHERAPY FOR BREAST CANCER

Impact Factor
8.01 (Year 2024)

UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now

Latest Publication

Recent Conferences

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024

Submit inquiry